Adamas Pharmaceuticals Inc. (ADMS) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other research firms also recently issued reports on ADMS. Mizuho reiterated a buy rating and set a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, September 23rd. Noble Financial began coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They set a buy rating and a $25.00 price target for the company. Credit Suisse Group AG reissued a buy rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities reissued a buy rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reissued an overweight rating and set a $44.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $32.11.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 15.67 on Tuesday. The company’s market capitalization is $343.63 million. The stock’s 50 day moving average price is $15.91 and its 200-day moving average price is $15.82. Adamas Pharmaceuticals has a 52-week low of $12.02 and a 52-week high of $31.84.
In other news, major shareholder Ix Lp Mdv acquired 50,919 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The shares were bought at an average price of $14.79 per share, with a total value of $753,092.01. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William W. Ericson acquired 43,719 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The shares were purchased at an average cost of $14.75 per share, for a total transaction of $644,855.25. The disclosure for this purchase can be found here. 31.79% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. Bow Street LLC purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at $7,369,000. Schwab Charles Investment Management Inc. increased its stake in Adamas Pharmaceuticals by 34.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 27,472 shares of the specialty pharmaceutical company’s stock valued at $416,000 after buying an additional 7,000 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at $158,000. Point72 Asset Management L.P. purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at $2,176,000. Finally, Highbridge Capital Management LLC purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at $205,000. 74.65% of the stock is currently owned by institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.
Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.